Renoprotective effects of chronic candesartan treatment in uninephrectomized rat

Mahmood S Mozaffari1, Kashyap B Patel, Stephen W Schaffer

  • 1Department of Oral Biology and Maxillofacial Pathology, Medical College of Georgia School of Dentistry, Augusta, Georgia 30912, USA. Mmozaffa@mail.mcg.edu

Insights

Chronic candesartan treatment, which blocks angiotensin II AT receptors, improved kidney function and reduced blood pressure in aging rats with one kidney. This suggests potential renoprotective effects in similar conditions.

Area of Science:

  • Nephrology
  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Aging and glucose intolerance impair renal excretory function, particularly in uninephrectomized individuals.
  • Angiotensin II AT receptors are implicated in age-dependent reductions in diuretic and natriuretic responses.

Purpose of the Study:

  • To investigate the role of angiotensin II AT receptors in age-related decline of renal function.
  • To test if chronic candesartan treatment preserves renal excretory function in aging uninephrectomized rats.

Main Methods:

  • Uninephrectomized control and glucose-intolerant rats were treated with candesartan or vehicle.
  • Renal excretory responses to plasma volume expansion were assessed in 9-month-old rats.
  • Mean arterial pressure, fluid and electrolyte excretion, glomerular filtration rate, and proteinuria were measured.

Main Results:

  • Candesartan treatment reduced mean arterial pressure in both rat groups.
  • Baseline and volume expansion-induced diuretic, natriuretic, and kaliuretic responses were enhanced by candesartan.
  • Candesartan increased glomerular filtration rate and reduced tubular reabsorption, improving saline volume-induced responses.
  • Proteinuria was reduced in candesartan-treated rats.

Conclusions:

  • Chronic blockade of angiotensin II AT receptors by candesartan exerts hypotensive and renoprotective effects.
  • Candesartan preserves renal excretory function in aging uninephrectomized rats, including those with glucose intolerance.
  • This suggests a therapeutic potential for angiotensin II receptor blockers in managing renal decline.